PARSIPPANY, N.J.-- Actavis Inc. said Friday a federal appeals court granted an injection that blocks it from selling a generic version of AstraZeneca PLC's asthma treatment Pulmicort Respules.» Read More
NEW YORK-- Shares of drug developer Insmed Inc. jumped Wednesday after a Lazard Capital Markets analyst started covering the stock, saying the shares could double in value over the next year. He said sales of Insmed's lung disease drug Arikace could reach more than $600 million a year by 2020..
PIERRE, S.D.-- Attorney General Marty Jackley says South Dakota will get more than $1 million as its share of a national settlement with a pharmaceutical manufacturer that allegedly distributed substandard drugs.
Actavis received and rejected a takeover offer from Mylan last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation said.
ZURICH, May 15- Swiss drugmaker Roche hopes data published this week will show it has a viable follow-on product to help fend off cheaper competition for its best-selling cancer drug, which loses patent protection in Europe later this year.
This marks the first companion diagnostic that detects epidermal growth factor receptor gene mutations to be approved by the U.S. Food and Drug Administration, the agency said.
*India is largest beneficiary in U.S. trade benefit program. WASHINGTON, May 14- A U.S. think tank on Tuesday recommended Congress suspend trade benefits for India, in the latest sign of U.S. frustration over Indian policies that block American exports and "free ride" on costly U.S. research to develop new medicines and other forms of valuable intellectual property.
The number of women choosing to have preventive mastectomies has risen by almost 50 percent in recent years, and surveys show they are happy with the decision.
Shares of genetic test maker rose 4 percent, after actress Anjolina Jolie said to undergo double-mastectomy, following testing which showed she carried a gene for breast cancer.
LAKE FOREST, Ill.-- Drug and medical device maker Hospira Inc. said Tuesday that Dr.
The FDA in January asked zolpidem manufacturers, including NovaDel Pharma Inc and Swedish drugmaker Meda, to reduce recommended dosages on the drugs' labels. The FDA recommended doses of 5 mg for women and either 5 mg or 10 mg for men for immediate-release zolpidem products such as Sanofi's Ambien.
BOTHELL, Wash.-- Drug developer Seattle Genetics Inc. said Tuesday the Food and Drug Administration has accepted its application to market the lymphatic cancer treatment Adcetris for some additional uses. Seattle Genetics expects the FDA to make a decision by Sept. 14.
Cramer doesn’t ordinarily recommend fresh IPOs immediately in the aftermarket. This one, however, is an exception.
NEW YORK-- PDI Inc., which provides sales and marketing services to the biopharmaceutical industry, said Monday that it turned a profit in the first quarter. Net income was $2.1 million, or 14 cents per share. The company had a loss of $272,000, or 2 cents per share, a year ago.
*Ranbaxy says money set aside sufficient to cover costs. May 13- Indian generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice.
*Ranbaxy majority-owned by Japan's Daiichi Sankyo. May 13- Indian drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice.
MOUNTAIN VIEW, Calif.-- Obesity drug maker Vivus Inc. on Monday named two new directors to its board as it finds itself in a proxy fight. CEO of German drugmaker Boehringer Ingelheim from 2003 to 2011, and Plutzky has directed the vascular disease prevention program at Brigham and Women's Hospital in Boston since 1996..
NEW YORK-- Shares of Warner Chilcott PLC rose before Monday's opening bell on optimism that it will eventually reach a deal to combine with fellow drugmaker Actavis Inc..
DUBLIN, May 13- Irish drugmaker Elan Corporation has agreed a $1 billion royalties deal that could soothe concerns about its potentially risky acquisition strategy and fend off a takeover bid from Royalty Pharma.
Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21 percent of the royalties that U.S. company Theravance receives from GlaxoSmithKline.
Companies like Pfizer Inc and AstraZeneca have grown dependent on higher U.S. prices to generate profits as generic rivals to their best-selling medicines enter the world market, Europe's government-run health plans clamp down on spending and sales growth in emerging markets stutters.